newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

  • Bezuclastinib achieved a mean Total Symptom Score (TSS) reduction of –32.0 points at 48 weeks, representing a 56% relative improvement from baseline.
  • 99% of patients experienced a reduction in serum tryptase of at least 50%, while 83.3% achieved normalization of the biomarker.
  • Significant improvements were observed across all measured symptom domains at 48 weeks, including dermatologic (–65.0%), neurocognitive (–53.6%), gastrointestinal (–62.5%), pain (–45.8%), & fatigue (–41.3%).
  • Strong evidence of disease modification was demonstrated through a clear correlation between serum tryptase reduction & symptomatic improvement, along with clinically meaningful gains in bone mineral density.
  • 50% of patients reduced or discontinued best supportive care medicines during the 48-week treatment period.
  • Cogent Biosciences announced inducement equity grants on February 25, 2026, awarding three new employees a total of 24,000 stock options & 21,000 restricted stock units (RSUs).
  • Clinical results from the pivotal SUMMIT trial were presented at the AAAAI Annual Meeting in Waltham, Mass. & Boulder, Colo. on February 28, 2026.